EPFL - Idorsia Joint Symposium

The symposium aims to tighten the relationship between EPFL and Idorsia, a Basel based biopharmaceutical company specialized in the discovery and development of small molecules to provide innovative therapeutic possibilities. Presentations and discussions will explore potential research and students collaborations.

A unique opportunity to exchange with actors from industry. The School of Life Sciences Innovation initiative Catalyze4Life encourage scientists and students interested in biopharmaceutical developments to attend.

Free registration required

PROGRAM

• 13:00 Welcoming word – Gisou van der Goot, School of Life Sciences Dean
• 13:10 Welcoming word – Martine Clozel, Idorsia CSO
• 13:20 'Microfluidic flow cytometry' – Philippe Renaud, EPFL
• 13:40 'Leveraging Orexin receptor structures for drug design – Christoph Sager and Catherine Vaillant, Idorsia
• 14:00 'Rational protein design driving innovation towards novel biologics and cell-based therapies' – Bruno Correia, EPFL
• 14:20 'Pyruvate Dehydrogenase Kinase (PDHK): a difficult to reach but appealing cancer target' – Cedric Leroy, Idorsia 14:40
• Coffee Break
• 15:20 'Perspective of industry projects for Master students' – Felix Naef, EPFL
• 15:40 'Atomistic modelling of stability and properties of drug molecules with machine learning' – Federico Giberti, EPFL
• 16:00 ‘Challenges in Maching Learning-assisted Drug Design (MLDD)’ – part I – Julien Hazemann and Lisa Liberatore, Idorsia
• 16:20 ‘Engineering dentritic cell vaccines for cancer immunotherapy’ – Miki De Palma, EPFL
• 16:40 ‘Challenges in Maching Learning-assisted Drug Design (MLDD)’ – part II – Julien Hazemann and Elisa Liberatore, Idorsia
• 17:00 Closing comments – Martin Vetterli, EPFL President
• 17:10 ‘How to strenghten ties between EPFL and Idorsia’ – Discussion (on invitation only)
• 18:30 End of Symposium